Literature DB >> 16125957

Comparative prognostic features of stage IIIAN2 and IIIB non-small-cell lung cancer patients treated with surgery after induction therapy.

Fabrice Barlési1, Christophe Doddoli, Jean-Philippe Torre, Roger Giudicelli, Pierre Fuentes, Pascal Thomas, Philippe Astoul.   

Abstract

OBJECTIVE: Induction Therapy (IT) before surgery emerged as a widely used strategy for IIIAN2 and selected IIIB NSCLC patients. However, IT is associated with a possible increase in postoperative complications. Consequently, selection of patients with the best chances to benefit from combined treatment is mandatory.
METHODS: Study recorded demographics, treatment and outcome of consecutive patients treated with IT plus surgery for IIIAN2 or IIIB NSCLC. Survival was analysed by Kaplan-Meier and prognostic factors were analysed by log-rank and Cox regression.
RESULTS: From 1993 to 2003, 155 patients (IIIAN2=95/IIIB=60) were treated. Complete resection was associated with a significant prolonged median survival both for IIIAN2 (20 vs 16 months, P=0.05) and IIIB (20 vs 15 months, P=0.02) patients. A lower risk of death for IIIAN2 patients was independently associated with postoperative mediastinal lymph node clearance (HR=0.45, 95%CI [0.25-0.81], P=0.009) and absence of postoperative complication (HR=0.54, 95%CI [0.31-0.93], P=0.02). Absence of blood vessel invasion only was identified as an independent predictor of a lower risk of death (HR=0.27, 95%CI [0.12-0.59], P=0.01) for stage IIIB patients.
CONCLUSIONS: Besides similarities as the role of a complete R0 resection, treatment-related factors influence outcome of IIIAN2 patients while disease-related factors prevail on survival of IIIB patients, in whom the benefit of IT is unclear.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16125957     DOI: 10.1016/j.ejcts.2005.06.018

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

1.  Analysis of prognostic factors for surgery after neo-adjuvant therapy for stage III non-small cell lung cancer.

Authors:  Xuefeng Zhou; Jianjun Wang; Jiashun Wang; Yongcheng Pan; Jingsong Li; Wendong Wang; Feng Zhao
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-12-24

2.  Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables.

Authors:  Thierry Berghmans; Marianne Paesmans; Jean-Paul Sculier
Journal:  Ther Adv Med Oncol       Date:  2011-05       Impact factor: 8.168

Review 3.  Blood vessel invasion as a strong independent prognostic indicator in non-small cell lung cancer: a systematic review and meta-analysis.

Authors:  Jun Wang; Jianpeng Chen; Xi Chen; Baocheng Wang; Kainan Li; Jingwang Bi
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

4.  Prognostic Factors of IIIAN2 Non-Small-Cell Lung Cancer after Complete Resection: A Systemic Review and Meta-analysis.

Authors:  Youyu Wang; Yanhui Wan; Youhui Qian
Journal:  Comput Math Methods Med       Date:  2021-12-13       Impact factor: 2.238

5.  Sunlight may increase the FDG uptake value in primary tumors of patients with non-small cell lung cancer.

Authors:  Hasan Mutlu; Abdullah Büyükçelik; Eser Kaya; Mustafa Kibar; Ertuğrul Seyrek; Sinan Yavuz; Züleyha Calikuşu
Journal:  Oncol Lett       Date:  2013-01-07       Impact factor: 2.967

6.  Care of patients with non-small-cell lung cancer stage III - the Central European real-world experience.

Authors:  Milada Zemanova; Robert Pirker; Lubos Petruzelka; Zuzana Zbozínkova; Dragana Jovanovic; Mirjana Rajer; Krisztina Bogos; Gunta Purkalne; Vesna Ceriman; Subhash Chaudhary; Igor Richter; Jirí Kufa; Lenka Jakubikova; Marius Zemaitis; Marketa Cernovska; Leona Koubkova; Zdenka Vilasova; Karin Dieckmann; Attila Farkas; Jelena Spasic; Katerina Fröhlich; Andreas Tiefenbacher; Virag Hollosi; Juraj Kultan; Iveta Kolarová; Jiri Votruba
Journal:  Radiol Oncol       Date:  2020-05-28       Impact factor: 2.991

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.